World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://www.wjon.org

Original Article

Volume 11, Number 4, August 2020, pages 150-157

Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience

Figure 2. (a) Kaplan-Meier curve of overall survival (OS) for 33 cancer patients who received immunotherapy with either nivolumab or pembrolizumab between January 1, 2014 and January 12, 2016. The mean OS in all patients was 272.99 days (95.0% confidence interval: 207.54 - 338.45). (b) Kaplan-Meier curve of OD according to the type of cancer. The median OSs by type were 198, 121 and 45 months for patients with lung, melanoma and other, respectively. None of the patients who had Hodgkin’s lymphoma or bladder cancer passed away, therefore mean and median survival for these patients were not computed.

**Table 1.** Patient Characteristics
Characteristics	Patients
^aSoft tissue sarcoma, gastric cancer and renal cell carcinoma.
Age (years), mean (median)	58.38 (61.5)
Sex, n (%)
Male	25 (73.5)
Female	9 (26.5)
Smoking, n (%)
No	17 (50)
Yes	17 (50)
Alcohol, n (%)
No	27 (79.4)
Yes	7 (20.6)
Stage, n (%)
I	2 (5.9)
II	4 (11.8)
III	4 (11.8)
IV	23 (67.6)
Missing	1 (2.9)
Primary tumor sites, n (%)
Lung	17 (50.0)
Melanoma	7 (20.6)
Lymphoma	4 (11.8)
Bladder	3 (8.8)
Other^a	3 (8.8)
Line of cancer treatment before immunotherapy with nivolumab or pembrolizumab, n (%)
1	14 (41.2)
2	6 (17.6)
3	6 (17.6)
4	2 (5.9)
5	2 (5.9)
7	1 (2.9)
Missing	3 (8.8)
Surgery, n (%)
No	16 (47.1)
Yes	18 (52.9)
Radiation therapy, n (%)
No	19 (55.9)
Yes	15 (44.1)

Table 1. Patient Characteristics

Characteristics

Patients

^aSoft tissue sarcoma, gastric cancer and renal cell carcinoma.

Age (years), mean (median)

58.38 (61.5)

Sex, n (%)

Male

25 (73.5)

Female

9 (26.5)

Smoking, n (%)

17 (50)

Yes

17 (50)

Alcohol, n (%)

27 (79.4)

Yes

7 (20.6)

Stage, n (%)

2 (5.9)

4 (11.8)

III

4 (11.8)

23 (67.6)

Missing

1 (2.9)

Primary tumor sites, n (%)

Lung

17 (50.0)

Melanoma

7 (20.6)

Lymphoma

4 (11.8)

Bladder

3 (8.8)

Other^a

3 (8.8)

Line of cancer treatment before immunotherapy with nivolumab or pembrolizumab, n (%)

14 (41.2)

6 (17.6)

2 (5.9)

1 (2.9)

Missing

3 (8.8)

Surgery, n (%)

16 (47.1)

Yes

18 (52.9)

Radiation therapy, n (%)

19 (55.9)

Yes

15 (44.1)

**Table 2.** Outcomes of Immunotherapy With Nivolumab or Pembrolizumab
Characteristics	Patients
Immunotherapy, n (%)
Nivolumab	22 (64.7)
Pembrolizumab	12 (35.3)
Line of immunotherapy, n (%)
1	2 (5.9)
2	15 (44.1)
3	6 (17.6)
4	7 (20.6)
5	1 (2.9)
6	2 (5.9)
8	1 (2.9)
Complications, n (%)
No	23 (67.6)
Yes	11 (32.4)

Table 2. Outcomes of Immunotherapy With Nivolumab or Pembrolizumab

Characteristics

Patients

Immunotherapy, n (%)

Nivolumab

22 (64.7)

Pembrolizumab

12 (35.3)

Line of immunotherapy, n (%)

2 (5.9)

15 (44.1)

6 (17.6)

7 (20.6)

1 (2.9)

2 (5.9)

1 (2.9)

Complications, n (%)

23 (67.6)

Yes

11 (32.4)